BioHeng - About the company
BioHeng is a series B company based in Nanjing (China), founded in 2017. It operates as a Provider of cell and gene therapy technologies and services. BioHeng has raised $105M in funding from investors like Decheng Capital, GL Ventures and Octagon Capital Advisors. The company has 130 active competitors, including 59 funded and 13 that have exited. Its top competitors include companies like Beam Therapeutics, eGenesis and Mammoth.
Company Details
Provider of cell and gene therapy technologies and services. The company offers services like minimally invasive gene editing, CRISPR-Cas9 based therapy solutions, and universal CAR-T therapy. The company provides products for CAR-T therapy. CAR-T immunotherapy has applications in immunology, cytology, gene editing, and clinical medicine.
- Website
- www.bioheng.com
- Email ID
- *****@bioheng.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2017
Location
Nanjing, China
Stage
Series B
Total Funding
$105M in 4 rounds
Latest Funding Round
Investors
Ranked
31st among 130 active competitors
Similar Companies
Sign up to download BioHeng's company profile
BioHeng's funding and investors
BioHeng has raised a total funding of $105M over 4 rounds. Its first funding round was on Feb 14, 2019. Its latest funding round was a Series B round on Jun 02, 2022 for $*****. 1 investor participated in its latest round. BioHeng has 7 institutional investors.
Here is the list of recent funding rounds of BioHeng:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 02, 2022 | 5837613 | Series B | 5861895 | 6868563 | 8857864 | 9687883 |
Jun 02, 2022 | 9639096 | Angel | 1282699 | 4487044 | 5605871 | |
Mar 24, 2021 | 5933212 | Series B | 4696359 | 1571361 |
Access funding benchmarks and valuations. Sign up today!View details of BioHeng's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
BioHeng's Competitors and alternates
Top competitors of BioHeng include Beam Therapeutics, eGenesis and Mammoth. Here is the list of Top 10 competitors of BioHeng, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Beam Therapeutics 2017, Cambridge (United States), Public | Developer of gene therapy using CRISPR base editing to treat diseases | $222M | 71/100 | |
2nd | eGenesis 2015, Cambridge (United States), Series D | Developer of a gene transplantation platform for humanizing pig cells | $495M | 65/100 | |
3rd |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
4th |  Scribe Therapeutics 2018, Alameda (United States), Public | Developer of a gene-editing platform using CRISPR technology | $120M | 65/100 | |
5th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 64/100 | |
6th | Locus Biosciences 2015, Raleigh (United States), Series B | Developer of therapeutics for infectious disease and inflammatory indications | $67.3M | 64/100 | |
7th |  Prime Medicine 2019, Cambridge (United States), Public | Developer of genetic therapies for a wide range of diseases | $315M | 63/100 | |
8th | Tessera Therapeutics 2017, Cambridge (United States), Series C | Provider of new genome engineering technology for treating multiple diseases | $610M | 63/100 | |
9th | _1558958387529.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kytopen 2017, Cambridge (United States), Series B | Developer of gene delivery systems for cell therapy | $44.5M | 61/100 | |
10th | _1576054856947.png?devicePixelRatio=2&height=30&width=30){kind=logo} Watchmaker Genomics 2018, Boulder (United States), Series A | Developer of gene-editing technology | $48.3M | 60/100 | |
31st | Provider of cell and gene therapy technologies and services | $105M | 41/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on BioHeng's competitors? Click here to see the top ones
BioHeng's Investments and acquisitions
BioHeng has made no investments or acquisitions yet.
Reports related to BioHeng
Here is the latest report on BioHeng's sector:
News related to BioHeng
•
Bioheng Therapeutics Announces Fda Clearance Of Ind Application For Cd7 Ucar T Cell Therapy In T-all/lblPR Newswire•Mar 05, 2025•BioHeng
•
•
Nolling Biotech completes 120 million yuan in Series B financing, led by Eli Lilly Asia FundPEdaily•Nov 14, 2021•BioHeng, LAV Asset Management, 3E Bioventures Capital, NLVC and 2 others
•
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.ICrowdNewswire•Jun 22, 2021•BioHeng
•
Beiheng Biotechnology completes 520 million RMB Series B financingPEdaily•Mar 26, 2021•BioHeng, Octagon Capital Advisors, Decheng Capital, BlueRun Ventures and 2 others
•
Bioheng Biotech to advance Allogeneic Immuno-Cell TherapiesBioSpectrum Asia•Mar 25, 2021•BioHeng, Shenzhen Capital Group, BlueRun Ventures, Octagon Capital Advisors and 2 others
•
Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell TherapiesPR Newswire•Mar 24, 2021•BioHeng, GL Ventures, Hillhouse Capital Group, Decheng Capital and 3 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about BioHeng
Explore our recently published companies
- JTDooley - South Africa based, Unfunded company
- Nils Rebehn - Unfunded company
- Professional Concrete Services - Unfunded company
- Lewis Crofters - United Kingdom based, Unfunded company
- Taufratshofer Bichtele - Germany based, Unfunded company
- Ben Pingel - Meridian based, Unfunded company
